Table 3.
Antimicrobial susceptibility pattern of all gram-negative bacterial isolates among the study participants (N = 152).
| Antibiotics | Total (N) |
Sensitive | Intermediate | Resistant | |||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||
| Gentamicin | (N = 133) | 84 | 63.2% | 15 | 11.3% | 34 | 25.6% |
| Amikacin | (N = 152) | 99 | 65.1% | 16 | 10.5% | 37 | 24.3% |
| Ciprofloxacin | (N = 152) | 62 | 40.8% | 46 | 30.3% | 44 | 28.9% |
| Levofloxacin | (N = 152) | 61 | 40.1% | 47 | 30.9% | 44 | 28.9% |
| TMP/SMX | (N = 133) | 77 | 57.9% | 10 | 7.51% | 46 | 34.58% |
| Cefotaxime | (N = 121) | 25 | 20.7% | 3 | 2.5% | 93 | 76.9% |
| Cefepime | (N = 152) | 56 | 36.8% | 0 | 0.0% | 96 | 63.2% |
| Ampicillin | (N = 121) | 0 | 0.0% | 0 | 0.0% | 121 | 100.0% |
| Piperacillin-tazobactam | (N = 152) | 70 | 46.0% | 1 | 0.7% | 81 | 53.3% |
| Ceftazidime | (N = 152) | 30 | 19.70% | 4 | 2.6% | 118 | 77.6% |
| Imipenem | (N = 152) | 101 | 66.4% | 3 | 2.0% | 48 | 31.6% |
| Meropenem | (N = 152) | 104 | 68.4% | 0 | 0.0% | 48 | 31.6% |
| Cefuroxime | (N = 121) | 15 | 12.4% | 8 | 6.6% | 98 | 81.0% |
| Ceftriaxone | (N = 121) | 25 | 20.7% | 3 | 2.5% | 93 | 76.9% |
| Amoxicillin-clavulanate | (N = 121) | 50 | 41.3% | 4 | 3.3% | 67 | 55.4% |
| Colistin | (N = 141) | 141 | 100.0% | 0 | 0.0% | 0 | 0.0% |